Rep. Maria Elvira Buys Biogen (BIIB) Stock

Representative Maria Elvira Discloses Biogen Purchase

Representative Maria Elvira, a member of the U.S. House of Representatives, recently disclosed a purchase of Biogen Inc. (NASDAQ: BIIB) stock. According to a periodic transaction report filed under the STOCK Act on June 9, 2026, the trade was valued in a range between $1,001 and $15,000. These disclosures are mandatory for members of Congress to ensure transparency regarding their financial activities.

Timing of the Biogen Trade

The transaction took place on May 12, 2026, but was not officially reported until June 9, 2026. This nearly month-long gap is standard under the STOCK Act, which gives politicians up to 45 days to disclose their trades. This isn't the first time Elvira has been active with this specific stock; prior coverage shows she reported selling a similar amount of Biogen shares on September 24, 2026. This back-and-forth activity highlights the periodic nature of these financial disclosures.

Biogen Stock Performance

On Saturday, Biogen shares were priced at $198.64. The stock has seen a fair amount of movement over the past year, reaching as high as $225.80 and dropping as low as $135.39. At the current price, the stock is trading just above its 200-day moving average, a common benchmark that helps investors see long-term price trends. With a market value of roughly $32.37 billion, Biogen remains a major player in the biotechnology space.

Recent Earnings and Growth

Biogen reported revenue of $10.03 billion for its most recent period, showing a small growth rate of about 3.4%. The company's earnings per share (EPS) reached $5.62, and it maintained a net margin of 8.3%. These figures provide a snapshot of the company's financial health as it prepares for its next earnings announcement, which is expected on October 28, 2026.

Analysts Set New Price Targets

Wall Street firms have been active in updating their views on Biogen recently. On October 12, 2026, JP Morgan upgraded the stock to an Overweight rating and raised its price target significantly to $300.00 from $210.00. A few days earlier, on October 9, 2026, UBS maintained a Buy rating and lifted its target to $270.00. Other firms like RBC Capital and Piper Sandler also hold positive ratings, with targets of $256.00 and $245.00, respectively. On the other hand, HSBC takes a more cautious stance, maintaining a Reduce rating with a $175.00 target as of September 10, 2026.

About Biogen Inc.

Biogen is a biotechnology company based in Cambridge, Massachusetts, that focuses on treatments for complex neurological diseases. It is well-known for its portfolio of drugs for multiple sclerosis, spinal muscular atrophy, and more recently, its efforts in Alzheimer's disease treatment through the drug Leqembi. The company's ability to develop new therapies for the brain and nervous system is a primary driver of investor interest.

What's Ahead for Biogen Inc.

Investors will likely watch the upcoming October 28, 2026, earnings report to see if the company can build on its recent revenue growth. While the trade by Representative Elvira provides a look into a politician's portfolio, these reports are backward-looking and do not necessarily predict future stock performance. They simply serve as a record of transactions after they have occurred.